The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy.
Using a simple method for the selection of hybrid cell growth from the cell fusion of pairs of existing hybridoma cell lines, 2 different hybrid-hybridoma cell lines were produced. Both hybrid-hybridomas secreted bi-specific antibody with similar specificity for human CD3 and for mouse Thy-l but in one case the parental antibody isotypes were both IgG2b and in the other case the CD3 antibody was IgG2b and the anti-Thy-l antibody was IgG2c. In a model in vitro system both bi-specific antibodies were able to elicit potent cell killing of a Thy-l expressing mouse tumour cell line by human effector cell blasts. The cell blasts were generated from resting peripheral blood mononuclear cells using a mitogenic monoclonal antibody (MAb) (YTH361). The parental anti-Thy-l IgG2b but not the IgG2c antibody was also able to mediate cell killing by ADCC. This ADCC killing was inhibited by a MAb to the CD16 Fc receptor but the killing elicited by the bi-specific antibodies was not. Both mechanisms of tumour cell killing may be of great potential in human tumour therapy with MAbs.
Clark
M
M
Department of Pathology, University of Cambridge, UK.
Gilliland
L
L
Waldmann
H
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002459:Cell Fusion; D003602:Cytotoxicity, Immunologic; D006825:Hybridomas / Q000276:immunology*; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D051381:Rats
D000911:Antibodies, Monoclonal